You are here

  • Home
  • Archive
  • Volume 76, Issue 4
  • SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis

Article metrics

Article menu
Download PDFPDF
Respiratory infection
Original research
SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis

 

Online download statistics by month:

Online download statistics by month: December 2020 to November 2024

AbstractFullPdf
Dec 202012751198256
Jan 2021464446115
Feb 202129929554
Mar 202111091034163
Apr 2021598594132
May 202141140676
Jun 202116816247
Jul 202116116047
Aug 202116716645
Sep 202132431538
Oct 202114714051
Nov 2021919027
Dec 202117518226
Jan 202214914645
Feb 202217817733
Mar 202215715554
Apr 202215815454
May 202214814136
Jun 20221039636
Jul 20221038827
Aug 2022828020
Sep 202212912634
Oct 202210810044
Nov 2022949031
Dec 2022737224
Jan 2023656315
Feb 202366637
Mar 2023878041
Apr 202311784
May 2023114124
Jun 202315531
Jul 202312052
Aug 202310221
Sep 20237430
Oct 202314441
Nov 202315568
Dec 20239542
Jan 20248445
Feb 20241351210
Mar 20241194517
Apr 2024615928
May 20241193114
Jun 202413302
Jul 202411312
Aug 202414012
Sep 202410921
Oct 202411522
Nov 202418234
Total947570261688